GSK sells Lucozade and Ribena to Suntory for £1.35bn

GlaxoSmithKline (GSK) has sold its Lucozade and Ribena drinks brands for £1.35bn to Japanese consumer goods company Suntory Beverage and Food.

Lucozade Sport ad
A recent Lucozade Sport ad, created by Grey London

Suntory will acquire global rights to the Ribena and Lucozade brands and GSK’s Coleford manufacturing site. Annual sales of the Lucozade and Ribena combined were about £0.5bn in 2012, GSK says.

The deal is a major coup for Suntory to boost its presence in Europe. It is best known in the region as the owner of the Orangina brand and a range of Japanese whisky. The strength of Suntory in markets outside Europe is likely to help the Lucozade and Ribena brands, which are currently only particularly well known in Britain and Ireland, boost their global appeal.

Some 700 GSK staff, including those in the marketing and commercial teams, will transfer across to Suntory, the majority of which will be UK based.

Last month GSK created a new management team for the Lucozade and Ribena business to ensure a “smooth and swift transition” for the brands’ divestment.

The senior team is led by Peter Harding, formerly GSK Great Britain and Ireland general manager for consumer healthcare. The team also consists of UK and Ireland marketing director Carol Smith, international marketing director Jon Roberts, sales director Gareth Smyth and Ireland country manager Rory Brennan. 

A new management team was also formed for the remainder of the businesses that make up GSK’s consumer healthcare division – which includes brands such as Sensodyne, Aquafresh and Beechams – led by Carlton Lawson.

David Redfern, GSK chief strategy officer, says: “Lucozade and Ribena are iconic brands that have made a huge contribution to GSK over the years, but now is the right time to sell them as we increase the focus of our Consumer Healthcare business and execute the delivery of our late stage pipeline of pharmaceuticals and vaccines.

“We believe the future of Lucozade and Ribena is in good hands given Suntory’s established beverages business, ambitious growth plans and also their recognition of the strong performance and capability of the GSK employees working on these products.”

GSK and Suntory expect the £1.35bn cash transaction to complete by the end of the year, subject to regulatory approvals. GSK’s share price was down 0.15 per cent to 1648.5p at the time of writing.

It is not yet known how Ribena and Lucozade’s ad agency relationships, with M&C Saatchi and Grey London respectively, will be affected by the deal.

Recommended

Knowledge Bank

Comments

    Leave a comment

    Close

    Discover even more as a subscriber

    This article is available for subscribers only.

    Sign up now for your access-all-areas pass.

    If you're an existing paid print subscriber find out how to get access here.

    Subscribers enjoy unlimited access to unrivalled coverage of the biggest issues in marketing, alongside practical advice from the digital experts at Econsultancy.

    With a subscription to Marketing Week Premium you will get full access to:

    > World-renowned columnists

    > Analysis & case studies

    > Exclusive leading-edge insight

    > Carefully curated reports & briefings from Econsultancy

    > Plus, much more including a £300 discount for the Festival of Marketing

    Subscribe now

    Got a question?

    Contact us on +44 (0)20 7292 3703 or email customerservices@marketingweek.com

    If you are looking for our Jobs site, please click here

    Subscribers enjoy unlimited access to unrivalled coverage of the biggest issues in marketing, alongside practical advice from the digital experts at Econsultancy.

    With a subscription to Marketing Week Premium you will get full access to:

    > World-renowned columnists

    > Analysis & case studies

    > Exclusive leading-edge insight

    > Carefully curated reports & briefings from Econsultancy

    > Plus, much more including a £300 discount for the Festival of Marketing

    Subscribe now